275 related articles for article (PubMed ID: 36262424)
1. A perspective to weaponize microRNAs against lung cancer.
Murugan D; Rangasamy L
Noncoding RNA Res; 2023 Mar; 8(1):18-32. PubMed ID: 36262424
[TBL] [Abstract][Full Text] [Related]
2. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Therapeutics in Cancer: Current Advances and Challenges.
Reda El Sayed S; Cristante J; Guyon L; Denis J; Chabre O; Cherradi N
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072348
[TBL] [Abstract][Full Text] [Related]
4. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
5. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
6. Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics.
Tyagi N; Arora S; Deshmukh SK; Singh S; Marimuthu S; Singh AP
J Biomed Nanotechnol; 2016 Jan; 12(1):28-42. PubMed ID: 27301170
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA therapeutics: the emerging anticancer strategies.
Jain CK; Gupta A; Dogra N; Kumar VS; Wadhwa G; Sharma SK
Recent Pat Anticancer Drug Discov; 2014; 9(3):286-96. PubMed ID: 24605908
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in miRNA Delivery Systems.
Dasgupta I; Chatterjee A
Methods Protoc; 2021 Jan; 4(1):. PubMed ID: 33498244
[TBL] [Abstract][Full Text] [Related]
9. Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments.
To KKW; Fong W; Tong CWS; Wu M; Yan W; Cho WCS
Expert Opin Drug Discov; 2020 Jan; 15(1):63-83. PubMed ID: 31739699
[No Abstract] [Full Text] [Related]
10. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Rupaimoole R; Slack FJ
Nat Rev Drug Discov; 2017 Mar; 16(3):203-222. PubMed ID: 28209991
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-targeted therapeutics for lung cancer treatment.
Xue J; Yang J; Luo M; Cho WC; Liu X
Expert Opin Drug Discov; 2017 Feb; 12(2):141-157. PubMed ID: 27866431
[TBL] [Abstract][Full Text] [Related]
12. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
Pandey M; Ojha D; Bansal S; Rode AB; Chawla G
Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
Koutsaki M; Spandidos DA; Zaravinos A
Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
[TBL] [Abstract][Full Text] [Related]
14. miRNA-Based Therapeutic Strategies.
Ishida M; Selaru FM
Curr Anesthesiol Rep; 2013 Mar; 1(1):63-70. PubMed ID: 23524956
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs and Their Big Therapeutic Impacts: Delivery Strategies for Cancer Intervention.
Holjencin C; Jakymiw A
Cells; 2022 Jul; 11(15):. PubMed ID: 35954176
[TBL] [Abstract][Full Text] [Related]
16. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).
Gambari R; Brognara E; Spandidos DA; Fabbri E
Int J Oncol; 2016 Jul; 49(1):5-32. PubMed ID: 27175518
[TBL] [Abstract][Full Text] [Related]
17. Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives.
Bravo-Vázquez LA; Méndez-García A; Rodríguez AL; Sahare P; Pathak S; Banerjee A; Duttaroy AK; Paul S
Front Bioeng Biotechnol; 2023; 11():1208547. PubMed ID: 37576994
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of MitomiRs in the Pathophysiology of Human Disease.
Duarte FV; Palmeira CM; Rolo AP
Adv Exp Med Biol; 2015; 888():123-54. PubMed ID: 26663182
[TBL] [Abstract][Full Text] [Related]
19. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents.
Baumann V; Winkler J
Future Med Chem; 2014; 6(17):1967-84. PubMed ID: 25495987
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.
Wang H; Jiang Y; Peng H; Chen Y; Zhu P; Huang Y
Adv Drug Deliv Rev; 2015 Jan; 81():142-60. PubMed ID: 25450259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
